Cellyan Biotechnology Co., Ltd (HKPD) income statement
HKPDNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Aug 7, 2026Score 3/30
$1.33−0.19 (-12.76%)
Close on Nov 18, 2026Market cap $21.75MP/E –Yield –
Cellyan Biotechnology Co., Ltd income statement
Ratios
Latest available, balances at Mar 31, 2026
Profitability, FY2026
- Gross margin
- 10.3%
- Operating margin
- -17.8%
- Net margin
- -8.5%
- Return on equity, FY2026
- -15.5%
Financial strength
- Current ratio
- 3.86
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 6.9%
Valuation
- P/E ratio
- –
- Price to sales
- 1.62
- Price to book
- 2.26
- Dividend yield
- –
See a number that looks wrong?